

01-08-02

A/Box Sq

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 35800-240749(5800-36A)

First Inventor or Application Identifier: Kapeller-Libermann et al

Title of Invention: 17867, A NOVEL HUMAN
AMINOPEPTIDASE

Express Mail Label No. EL868637526US

ADDRESS TO: **BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231**

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Rosana Kapeller-Libermann, Chestnut Hill, MA
Mark Williamson, Saugus, MA

Assignee of this invention is Millennium Pharmaceuticals, Inc.

1. ☒ The Filing Fee has been calculated as shown below:
2. ☐ Applicant claims Small Entity Status. See 37 CFR 1.27.

| | No. Filed | No. Extra | Small Entity Rate | Fee 0 | Large Entity Rate | Fee 1 |
|---|-----------|-----------|----------------------|--------|----------------------|--------|
| BASIC FEE | | | | \$0 | | \$ 740 |
| TOTAL CLAIMS: | 22 - 20 = | 2 | X 9 = | \$0 | x 18 = | \$ 36 |
| INDEP CLAIMS: | 2 - 3 = | 0 | X 42 = | \$0 | x 84 = | \$ 0 |
| [<input type="checkbox"/>] MULTIPLE DEPENDENT CLAIMS PRESENTED | | | | +140 = | | \$ |
| *If the difference in Column 1 is less than zero, enter "0" in Column 2. | | | TOTAL | \$ | TOTAL | \$ 776 |

The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Acct.
No. 16-0605.

- a. ☒ Fees required under 37 CFR 1.16 (National filing fees).
- b. ☒ Fees required under 37 CFR 1.17 (National application processing fees).
- ☐ A check in the amount of \$ ___ for the filing fee is enclosed.
- ☐ The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.
3. ☒ Specification; Total Pages 78
4. ☒ 10 Sheets of Drawing(s) (35 USC 113)
5. ☒ Declaration and Power of Attorney; [Total Pages 6]
- a. ☐ Newly executed (original or copy)
- b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
6. ☐ Application Data Sheet. See 37 CFR 1.76
7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- a. ☒ Computer Readable Copy (CRF)
 - b. ☐ Request for Transfer of Computer Readable Form of Sequence Listing under 37 CFR § 1.821(e) and MPEP 2422.05 (must be compliant with new rules)
 - c. ☒ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ Paper (9 Pages)
 - d. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS


- 9. ☐ Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)
- 10. ☐ 37 CFR 3.73(b) Statement (*when there is an assignee*); ☐ Power of Attorney
- 11. ☐ English Translation Document (*if applicable*)
- 12. ☒ Information Disclosure Statement (IDS)/PTO-1449; 0 Copies of IDS Citations
- 13. ☐ Preliminary Amendment
- 14. ☒ Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)
- 15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
☐ Foreign Priority is claimed as Application No. , filed
- 16. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i).
Applicant **must** attach form PTO/SB35 or its equivalent.
- 17. ☐ Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.
- 18. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:**
 - ☒ Continuation ☐ Divisional ☐ Continuation in Part (CIP)of prior Application No: 09/345,650; Filed June 30, 1999

Prior Application Information: Examiner A. Harris Group/Art Unit: 1642

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. **CORRESPONDENCE ADDRESS** **CUSTOMER NUMBER 00826**


Signature:


Attorney of Record: Eric J. Kron
Attorney Registration No. 45,941

Alston & Bird LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF EXPRESS MAILING

"Express Mail" mailing label number EL868637526US
Date of Deposit December 31, 2001
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.


Nora C. Martinez

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Kapeller-Libermann et al. Confirmation No.: Not Assigned
Appl. No.: Not Assigned
Filed: Concurrently Herewith
For: 17867, A NOVEL HUMAN AMINOPEPTIDASE


**STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)**

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.

Respectfully submitted,


Eric J. Kron
Attorney/Agent for Applicant
Registration No. 45,941


Customer No. 00826

Alston & Bird LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

"Express Mail" Mailing Label Number EL868637526US
Date of Deposit: December 31, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner for Patents, Washington, DC 20231.


Nora C. Martinez